Medical technology megafirm Hologic (NASDAQ: [[ticker:HOLX]]), which develops diagnostics, imaging tools, and other devices focused on women’s healthcare, announced today that it will sell the rights to its drug Gestiva for $82 million in cash to St. Louis, MO-based KV Pharmaceutical. Bedford, MA-based Hologic acquired the rights to Gestiva, a treatment for the prevention of preterm birth, in its $6.2 billion merger with Cytyc back in the fall. Hologic won’t collect $82 million of the purchase price for Gestiva until the drug earns FDA approval.
Author: Rebecca Zacks
Rebecca is Xconomy's co-founder. She was previously the managing editor of Physician's First Watch, a daily e-newsletter from the publishers of New England Journal of Medicine. Before helping launch First Watch, she spent a decade covering innovation for Technology Review, Scientific American, and Discover Magazine's TV show. In 2005-2006 she was a Knight Science Journalism Fellow at MIT. Rebecca holds a bachelor's degree in biology from Brown University and a master's in science journalism from Boston University.
View all posts by Rebecca Zacks
